Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

DRD2 rs1800497 and ABCB1 3435C>T are associated with the safety of antipsychotics in adolescents with an acute psychotic episode: results of a pilot study

https://doi.org/10.14412/2074-2711-0-0-

Full Text:

Abstract

INTRODUCTION. Children and adolescents are more likely to experience adverse side effects when taking antipsychotics. Pharmacogenetic testing allows a more accurate selection of the initial dose of the drug. Genes of pharmacokinetic factors were shown to have high predictive value for the safety of antipsychotics in adults. Virtually no such studies have been conducted in adolescents with an acute psychotic episodes.

MATERIALS AND METHODS. The study enrolled 36 adolescents (mean age 14.83±1.84 years, 58.3% males). All patients were on antipsychotics. The observation lasted 28 days. The effectiveness and safety of treatment was assessed at 14th and 28th days using CGAS, PANSS, UKU SERS, SAS, BARS scales. Patients were genotyped for CYP3A4*22, CYP3A5*3, CYP2D6*4, *9, *10, ABCB1 1236C>T, 2677G>T/A, 3435C>T, DRD2 rs1800497, DRD4 rs1800955, HTR2A rs6313 polymorphisms.

RESULTS. The score of PANSS subscale "Productive symptomatology» decreased significantly in carriers of DRD2 rs1800497 at 14th day ((-6,5) [-10,25; -3,75] vs (-3) [-6,5; -2]; p=0,028) and on day 28 ((-11) [-13; -9,5] vs (-5) [-9; -3,5]; p=0,001). ABCB1 3435 CT+TT was associated with the worse tolerance of pharmacotherapy at 14th day (total UKU SERS scale score M=8 [3; 11.75] vs M=2 [1; 6]; p=0.034). Carriers of DRD2 rs1800497 noted a greater severity of antipsychotic-induced neurological symptoms (score of UKU SERS M=1 [0; 2,25] vs M=0 [0; 1]; p=0,029).

CONCLUSION. It was established that DRD2 rs1800497 and ABCB1 3435C>T polymorphisms were significantly associated with the efficacy and safety of antipsychotics in adolescents with acute psychotic episode.

About the Authors

D. V. Ivashchenko
Russian Medical Academy of Continuous Professional Education
Russian Federation

Dmitriy V. Ivashchenko, MD, PhD

125993, Barrikadnaya, 2/1-1, Moscow



S. Z. Choang
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Moscow


M. Kh. Tazagulova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Moscow


B. V. Makhmudova
Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University
Russian Federation
Moscow


N. I. Buromskaya
Scientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva
Russian Federation
Moscow


P. V. Shimanov
Scientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva
Russian Federation
Moscow


R. V. Deitch
Scientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva
Russian Federation
Moscow


I. V. Dorina
Scientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva
Russian Federation
Moscow


M. I. Nastovich
Scientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva
Russian Federation
Moscow


K. A. Akmalova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Moscow


A. A. Kachanova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Moscow


E. A. Grishina
Russian Medical Academy of Continuous Professional Education
Russian Federation
Moscow


L. M. Savchenko
Russian Medical Academy of Continuous Professional Education
Russian Federation
Moscow


Yu. S. Shevchenko
Russian Medical Academy of Continuous Professional Education
Russian Federation
Moscow


D. A. Sychev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Moscow


References

1. Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303–18

2. Balijepalli C, Druyts E, Zoratti MJ et al. Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis. Schizophr Res Treatment. 2018; 2018:1–9.

3. Zhai D, Lang Y, Feng Y et al. Early onset of cardiometabolic risk factor profiles in drug naïve adolescents and young adults with first-episode schizophrenia. Schizophr Res. 2017;190:60–2.

4. Eum S, Lee AM, Bishop JR. Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci. 2016; 18(3):323–37.

5. Xiang Q, Zhao X, Zhou Y et al. Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety. J Clin Pharmacol. 2010;50(6):659–66.

6. Kim K-A, Joo H-J, Lee H-M et al. Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet Genomics. 2014;24(1):35–42.

7. Wolking S, Schaeffeler E, Lerche H et al. Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. Clinical Pharmacokinetics. 2015; 54(7): 709–35.

8. Rafaniello C, Sessa M, Bernardi FF et al. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J. 2018;18(3):422–30.

9. Mi W, Liu F, Liu Y et al. Association of ABCB1 Gene Polymorphisms with Efficacy and Adverse Reaction to Risperidone or Paliperidone in Han Chinese Schizophrenic Patients. Neurosci Bull. 2016;32(6):547–9.

10. Zhang J-P, Lencz T, Malhotra AK. D2 Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis. Am J Psychiatry. 2010;167(7):763–72.

11. Ma L, Zhang X, Xiang Q et al. Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis. Basic Clin Pharmacol Toxicol. 2019;124(1):94–104.

12. Wehry AM, Ramsey L, Dulemba SE et al. Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. Curr Probl Pediatr Adolesc Health Care. 2018;48(2):40–9.

13. Ivanova SA, Filipenko ML, Vyalova NM et al. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. Bull Exp Biol Med. 2016;160(5):687–90.

14. Ito T, Yamamoto K, Ohsawa F et al. Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study. J Pharm Heal Care Sci. 2018;4(1):28.

15. Gardner DM, Murphy AL, O’Donnell H et al. International Consensus Study of Antipsychotic Dosing. Am J Psychiatry. 2010;167(6):686–93.

16. Shaffer D, Gould MS, Brasic J et al. A Children’s Global Assessment Scale (CGAS). Arch Gen Psychiatry. 1983;40(11):1228.

17. Kay SR, Opler LA, Spitzer RL et al. SCID-PANSS: two-tier diagnostic system for psychotic disorders. Compr Psychiatry. 1991;32(4):355–61.

18. Lingjaerde O, Ahlfors UG, Bech P et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100.

19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–9.

20. Barnes TRE. The Barnes Akathisia Rating Scale–Revisited. J Psychopharmacol. 2003;17(4):365–70.

21. Gassó P, Mas S, Álvarez S et al. Xenobiotic metabolizing and transporter genes: gene–gene interactions in schizophrenia and related disorders. Pharmacogenomics. 2010;11(12):1725–31.

22. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet. 2003;116B(1):103–25.

23. Kurylev AA, Brodyansky VM, Andreev BV et al. The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study). Psychiatr Danub. 2018;30(2):157–63.

24. Ikeda M, Yamanouchi Y, Kinoshita Y et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. 2008;9(10):1437–43.

25. Escamilla R, Camarena B, Saracco R et al. Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia. Neuropsychiatr Dis Treat. 2018;14:2981–7.

26. Kang S-G, Na K-S, Lee H-J et al. DRD2 Genotypic and Haplotype Variation Is Associated With Improvements in Negative Symptoms After 6 Weeks’ Amisulpride Treatment. J Clin Psychopharmacol. 2015;35(2):158–62.

27. Vehof J, Burger H, Wilffert B et al. Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes. Eur Neuropsychopharmacol. 2012;22(9):625–31.

28. Hattori S, Suda A, Kishida I et al. Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia. BMC Psychiatry. 2018;18(1):231.

29. Consoli G, Lastella M, Ciapparelli A et al. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics. 2009;10(8):1267–76.

30. Saiz-Rodríguez M, Belmonte C, Román M et al. Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. Basic Clin Pharmacol Toxicol. 2018;123(4):474–85.

31. Suzuki Y, Tsuneyama N, Fukui N et al. Impact of the ABCB1 Gene Polymorphism on Plasma 9-Hydroxyrisperidone and Active Moiety Levels in Japanese Patients With Schizophrenia. J Clin Psychopharmacol. 2013;33(3):411–4.

32. Gassó P, Mas S, Bioque M et al. Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. J Psychopharmacol. 2018;32(6):702–10.

33. Miura I, Zhang J-P, Hagi K et al. Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. Psychoneuroendocrinology. 2016;72:1–10.

34. Mas S, Gassó P, Torra M et al. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. Eur Neuropsychopharmacol. 2017;27(7):647–56.

35. Jovanović N, Božina N, Lovrić M et al. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol. 2010;66(11):1109–17.


For citation:


Ivashchenko D.V., Choang S.Z., Tazagulova M.K., Makhmudova B.V., Buromskaya N.I., Shimanov P.V., Deitch R.V., Dorina I.V., Nastovich M.I., Akmalova K.A., Kachanova A.A., Grishina E.A., Savchenko L.M., Shevchenko Y.S., Sychev D.A. DRD2 rs1800497 and ABCB1 3435C>T are associated with the safety of antipsychotics in adolescents with an acute psychotic episode: results of a pilot study. Neurology, Neuropsychiatry, Psychosomatics. 0;. (In Russ.) https://doi.org/10.14412/2074-2711-0-0-

Views: 34


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)